|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.
|
24444868 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.
|
24997151 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared to CD45-low patients, CD45-high patients had a lower event-free survival rate (B-cell-precursor acute lymphoblastic leukemia: 72 ± 3% versus 86 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 60 ± 8% versus 78 ± 4%, P=0.02), which was mainly attributable to a higher cumulative relapse incidence (B-cell-precursor acute lymphoblastic leukemia: 22 ± 3% versus 11 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 31 ± 8% versus 11 ± 3%, P=0.003) and kept its significance in multivariate analysis considering sex, age, initial white blood cell count, and minimal residual disease in B-cell-precursor- and T-cell acute lymphoblastic leukemia, and additionally presence of ETV6/RUNX1, MLL/AF4 and BCR/ABL1 rearrangements in B-cell-precursor acute lymphoblastic leukemia (P=0.002 and P=0.025, respectively).
|
23911702 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The prognostic value of IKZF1 deletions was evaluated in 2 cohorts of BCR-ABL1-positive BCP-ALL patients, before tyrosine kinase inhibitors (pre-TKI) and after introduction of imatinib (in the European Study for Philadelphia-Acute Lymphoblastic Leukemia [EsPhALL]).
|
24366361 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The incorporation of ABL kinase inhibitors into acute lymphoblastic leukemia management should serve as a model for incorporation of FLT3-targeted agents into clinical care.
|
24468836 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.
|
24280866 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.
|
23804397 |
2013 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
After the successful use of tyrosine kinase inhibitors in the treatment of BCR-ABL1-positive acute lymphoblastic leukemia, patients with alternative ABL1 translocations and rearrangements involving PDGFRB may benefit from treatment with tyrosine kinase inhibitors.
|
24319172 |
2013 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
|
22997141 |
2013 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
|
23881917 |
2013 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Additional chromosome abnormalities (ACAs), mutations of the BCR-ABL tyrosine kinase domain (TKD) and BCR-ABL splice variants may cause resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoid leukemia (ALL).
|
22005133 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients.
|
22587422 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
|
22591684 |
2012 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recurrent genetic abnormalities in B-lymphoblastic leukemia with prognostic significance are well known and specifically delineated in the WHO 2008 classification (eg hyperdiploidy, t(9;22)(q34;q11.2); BCR-ABL1, t(12;21)(p13;q22); ETV6-RUNX1).
|
21822204 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
|
21863287 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
|
21178708 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Altogether, our data suggest that AMPK is an attractive target for the treatment of BCR-ABL-expressing malignancies and raise the potential for use of AMPK activators in the treatment of refractory chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.
|
22021366 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
|
22134481 |
2011 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.
|
19759560 |
2010 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The breakpoint on chromosome 9 is mostly 5' to ABL1 exon 2, whereas on chromosome 22, the breakpoint can occur in various regions involving the major breakpoint cluster region (M-bcr) in CML and the minor breakpoint cluster region (m-bcr) in acute lymphoblastic leukemia.
|
20633771 |
2010 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PAX5 deletions are frequent in adult BCR-ABL1-positive acute lymphoblastic leukemia and are not associated with a poor outcome.
|
20534699 |
2010 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
|
19770381 |
2009 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
|
19095773 |
2009 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases.
|
19816207 |
2009 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
|
19587702 |
2009 |